{
    "Trade/Device Name(s)": [
        "EUROIMMUN Anti-West Nile Virus ELISA (IgG)"
    ],
    "Submitter Information": "EUROIMMUN US, Inc.",
    "510(k) Number": "K153303",
    "Predicate Device Reference 510(k) Number(s)": [
        "K031953"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NPO"
    ],
    "Summary Letter Date": "July 8, 2016",
    "Summary Letter Received Date": "July 12, 2016",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.3940"
    ],
    "Regulation Name(s)": [
        "West Nile Virus Serological Reagent"
    ],
    "Analyte Class(es)": [
        "virology",
        "serology"
    ],
    "Analyte(s)": [
        "West Nile virus IgG antibodies"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "Li-heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Microplate ELISA reader"
    ],
    "Method(s)/Technology(ies)": [
        "ELISA"
    ],
    "Methodologies": [
        "Immunoassay",
        "Enzyme-linked immunosorbent assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for EUROIMMUN Anti-West Nile Virus ELISA (IgG), a qualitative ELISA assay for detecting IgG antibodies to West Nile virus in serum and plasma.",
    "Indications for Use Summary": "Intended for the qualitative detection of IgG antibodies to West Nile virus in human serum and plasma as an aid in the presumptive laboratory diagnosis of West Nile virus infection in patients with symptoms consistent with meningitis/encephalitis, in conjunction with other laboratory and clinical findings.",
    "fda_folder": "Microbiology"
}